Skip to main
NMRA

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Neumora Therapeutics is well-positioned for success with its diversified pipeline targeting novel mechanisms of action, including its lead program NMRA-140 for treatment-resistant depression. While the company faced a setback with the delay of its NMRA-215 program due to unexpected rat toxicology findings, the management team remains confident in the potential of the drug and has taken necessary steps to address the issue. With multiple near-term catalysts and a strong cash position, Neumora is poised for growth and has the potential for a meaningful re-rating.

Bears say

Neumora Therapeutics is facing a setback as it announces discontinuation of navacaprant development following negative results in its KOASTAL-2/3readout and a 35% reduction in workforce. This lowering of PT from $8 to $5 is largely due to the discontinuation of navacaprant and the potential loss of an effective treatment option with a large market potential of $3B at peak. However, the company still has a good chance of success with its remaining pipeline and a potential upside of $750M in US sales for MDD treatment by 2028. As a result, investors should carefully consider the company's remaining pipeline offerings and long-term growth potential before making any investment decisions.

NMRA has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 7 analysts, NMRA has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.